Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: Implications for in vitro susceptibility breakpoints

Journal of Infectious Diseases

Volumn 206, Issue 3, 2012, Pages 442-452

  Jeans, Adam R ^a   Howard, Susan J ^a   Al Nakeeb, Zaid ^a   Goodwin, Joanne ^a   Gregson, Lea ^a   Majithiya, Jayesh B ^a   Lass Flörl, Cornelia ^b   Cuenca Estrella, Manuel ^c   Arendrup, Maiken C ^d   Warn, Peter A ^a   Hope, William W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; BIOREACTOR DESIGN; CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; ENDOTHELIUM CELL; FUNGAL STRAIN; FUNGUS ISOLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; LUNG ALVEOLUS; LUNG ASPERGILLOSIS; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE, FUNGAL; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MANNANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PULMONARY ARTERY; PYRIMIDINES; RESPIRATORY MUCOSA; TRIAZOLES;

EID: 84863895794     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis372     Document Type: Article

References (18)

1. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47:1176-84.
2. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15:1068-76.
3. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5:e219.
4. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
5. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
6. Hope WW, Kruhlak MJ, Lyman CA, et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 2007; 195:455-66.
7. Wasylnka JA, Moore MM. Uptake of Aspergillus fumigatus conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein. Infect Immun 2002; 70:3156-63.
8. Howard SJ, Lestner JM, Sharp A, et al. Pharmacokinetics and Pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis 2011; 203:1324-32.
9. Leary R, Jelliffe R, Schumitzky A, van Guilder M. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Program and abstracts of the 14th IEEE Symposium on Computer-Based Medical Systems (Bethesda, MD). Washington, DC: IEEE, 2001: 389-94.
10. Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother 2012; 56:526-31.
11. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource, 2009.
12. Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 2010; 48:3251-7.
13. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003; 31:731-41.
14. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47:3165-9.
15. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55:4782-8.
16. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-11.
17. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-43.
18. Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother 1994; 38:1386-91.